Pharma Mar, S.A.

MCE PHM.MC

Pharma Mar, S.A. Total Non-Current Liabilities for the year ending December 31, 2023: USD 57.28 M

Pharma Mar, S.A. Total Non-Current Liabilities is USD 57.28 M for the year ending December 31, 2023, a -26.64% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Pharma Mar, S.A. Total Non-Current Liabilities for the year ending December 31, 2022 was USD 78.09 M, a -34.12% change year over year.
Pharma Mar, S.A. Total Non-Current Liabilities for the year ending December 31, 2021 was USD 118.53 M, a -26.84% change year over year.
Pharma Mar, S.A. Total Non-Current Liabilities for the year ending December 31, 2020 was USD 162.00 M, a 154.11% change year over year.
Pharma Mar, S.A. Total Non-Current Liabilities for the year ending December 31, 2019 was USD 63.75 M, a -17.86% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

MCE: PHM.MC

Pharma Mar, S.A.

CEO	Mr. Jose Maria Fernandez Sousa-Faro Ph.D.
IPO Date	Sept. 8, 2000
Location	Spain
Headquarters	Avenida de los Reyes, 1
Employees	509
Sector	Healthcare
Industries Biotechnology Pharmaceuticals Plastics

Description

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Key trends

Past 5 years